Clinical trial
Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable…
NCT00262769 · University College, London, Other · Completed
Key facts
| NCT number | NCT00262769 |
|---|---|
| Title | Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors |
| Official title | Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study |
| Acronym | ABC-02 |
| Lead sponsor | University College, London, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gemcitabine hydrochloride |
| Enrollment | 324 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2008 |
| First posted | Dec 7, 2005 |
| Last update posted | Jul 17, 2012 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: